9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Pleural Mesothelioma Malignant Advanced

Estimated Enrollment: 144

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Progression Free Survival (PFS) in patients with advanced pre-treated malignant mesothelioma.,  Objective response.,  Overall survival., Time to treatment failure.

Interventions: Pembrolizumab, Gemcitabine

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: December 2020

Completion Date: December 2020

Last  Posted Date: July 22, 2019

Location: ICO Hospitalet, Barcelona, Spain

Website Link: https://ClinicalTrials.gov/show/NCT02991482

Was this article helpful?
Dislike 0